Ranok Therapeutics
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Suite 1005 Building 1 501 2nd Avenue Qia...Phone Number
+86 57186630936Website
www.ranoktherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Ranok Therapeutics
Ranok Therapeutics, headquartered in Hangzhou, China, is a biotech and pharmaceutical company that specializes in protein degradation technology.Explore more
Ranok Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ranok Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Ranok Therapeutics recently announced quarterly report
Check if Ranok Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Ranok Therapeutics has new funding data
Ranok Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Ranok Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Ranok Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Ranok Therapeutics
Check out if Ranok Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Ranok Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
Ranok Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ranok Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ranok Therapeutics.
Ranok Therapeutics financials insights
Gather financial insights about Ranok Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$10M
2021
Series B
$40M
Ranok Therapeutics Tech Stack
A closer look at the technologies used by Ranok Therapeutics
Ranok Therapeutics News & Media
Ranok Therapeutics Announces the Publication of Positive Phase 1a Clinical Results for KRAS G12D Inhibitor RNK08954 in Cancer Discovery
BOSTON and HANGZHOU, China, May 11, 2026 /PRNewswire/ -- Ranok Therapeutics, a clinical-stage biotechnology company developing innovative therapies, today announced the publication of preliminary clinical results from its Phase 1a study of RNK08954 in the peer-reviewed journal Cancer Discovery. RNK08954 is a proprietary, highly selective, oral small-molecule inhibitor targeting KRAS G12D mutation in patients with advanced solid tumors. The study evaluated the safety, tolerability, and clinical aRanok Therapeutics Expands Clinical Testing of CHAMP® BRD4 Protein Degrader RNK05047 to China
BOSTON & HANGZHOU, China--(BUSINESS WIRE)--Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancers, today announced the initiation of patient dosing in China for a Phase 1 study of RNK05047, its first protein degrader candidate. The study, which mirrors an ongoing Phase 1 study in the U.S., will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RNK05047 in Chinese paWeek In Review: China And The U.S. May Settle De-Listing/Accounting Impasse
According to a WSJ report, China and US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges.Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP™ Protein Degrader
BOSTON & HANGZHOU, China--(BUSINESS WIRE)--Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today announced the initiation of patient dosing in the U.S. for a Phase 1/2 study of RNK05047. The trial, entitled CHAMP-1, will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RNK05047 in patients with advanced solid tumors or diffuse larg
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ranok Therapeutics
Sign Up For FreeTo access detailed company insights
Ranok Therapeutics, headquartered in Hangzhou, China, is a biotech and pharmaceutical company that specializes in protein degradation technology.... Read More
